RNAi Roundtable: ALN-6400, An Investigational RNAi Therapeutic Targeting Plasminogen to Address Rare Bleeding Disorders

25 Jun, 2026 RNAi Roundtable: ALN-6400, An Investigational RNAi Therapeutic Targeting Plasminogen to Address Rare Bleeding Disorders

On June 25, 2026, we hosted an online RNAi Roundtable to review progress with ALN-6400, an investigational RNAi therapeutic in development to address rare bleeding disorders.

Access the replay
View the presentation

Pushkal Garg, M.D.
Chief Research & Development Officer

John Gansner, M.D., Ph.D.
Executive Director, ALN-6400 Program Lead

Hanny Al-Samkari, M.D.
Associate Professor of Medicine, Harvard Medical School
Peggy S. Blitz Endowed Chair in Hematology/Oncology and Co-Director, HHT Center of Excellence, Massachusetts General Hospital

Martina Slingsby, Ph.D.
Senior Clinical Scientist, ALN-6400 Clinical Science Lead